Poornima Vinod, MD
Internal Medicine · Lebanon, NHNPI 1639555386
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $452 of the $583 with a category attached, or 77.7%. It is spread thinly across 15 manufacturers, the largest accounting for just 22.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $256, 2.3 times the $112 reported in 2019.
Across 23 payments — averaging $25.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$130
- Abbott$71
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$67
- Pfizer$42
- AstraZeneca$38
- E.r. Squibb & Sons, L.L.C.$34
- plus $200 from 9 others
What the payments were for
- Consulting fees$13022%
- Food & beverage$45278%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 1 | $130 |
| Abbott | 3 | $71 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $67 |
| Pfizer | 3 | $42 |
| AstraZeneca | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Johnson & Johnson | 2 | $33 |
| Terumo Medical Corporation | 1 | $30 |
| Amarin Pharma, Inc. | 1 | $23 |
| Boston Scientific | 2 | $23 |
| Novartis | 1 | $23 |
| Insulet Corporation | 1 | $21 |
| Ironwood Pharmaceuticals, Inc | 1 | $20 |
| AbbVie | 1 | $14 |
| Novo Nordisk | 1 | $13 |
How this compares
$583 in reported general payments places this provider in the 85th percentile of 504 internal medicine providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 17 | $509 |
| Atorvastatin Calcium | 46 | $235 |
| Metoprolol Succinate | 14 | $199 |
| Losartan Potassium | 12 | $171 |
| Metoprolol Tartrate | 17 | $115 |
| Lisinopril | 16 | $84 |
| Oxybutynin Chloride | 13 | $82 |
| Metformin Hcl | 17 | $80 |
| Amlodipine Besylate | 24 | $58 |
| Carvedilol | 12 | $57 |
| Hydrochlorothiazide | 16 | $26 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Lebanon
- Deborah TepperLebanon$133K
- William MonacoLebanon$97K
- Mary McGowanLebanon$26K
- Daniel FeldmanLebanon$17K
- Amir Soheil TolebeyanLebanon$13K
- Scott RizziLebanon$13K
- Jonathan LurieLebanon$8K
- Lisa AdamsLebanon$4K
- Julia LakeLebanon$3K
- Stephen LiuLebanon$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.